Provided by Tiger Trade Technology Pte. Ltd.

TransCode Therapeutics Inc.

8.98
-0.3300-3.54%
Post-market: 9.110.1300+1.45%19:39 EDT
Volume:14.14K
Turnover:126.60K
Market Cap:8.23M
PE:-0.04
High:9.30
Open:9.30
Low:8.79
Close:9.31
52wk High:46.76
52wk Low:6.08
Shares:916.97K
Float Shares:832.40K
Volume Ratio:1.53
T/O Rate:1.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-236.5200
EPS(LYR):-1,317.4218
ROE:-1763.01%
ROA:-232.54%
PB:5.77
PE(LYR):-0.01

Loading ...

TransCode Therapeutics Issues 1.14M Non-Voting Convertible Preferred Shares in Private Placement

Reuters
·
Mar 04

TransCode Therapeutics Expands Pipeline With Oncolytic Virus Deal

TIPRANKS
·
Mar 04

Transcode Therapeutics enters exclusive license agreement with Unleash

TIPRANKS
·
Mar 03

BRIEF-Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash

Reuters
·
Mar 03

Transcode Therapeutics Inc - Under Agreement, Unleash to Receive 1,136,364 Shares of Transcode Preferred Stock

THOMSON REUTERS
·
Mar 03

TransCode Therapeutics licenses Unleash oncolytic immunotherapy platform in all-stock deal

Reuters
·
Mar 03

TransCode Therapeutics Publishes Preclinical Results for Tumor-Selective RIG-I Immunotherapy Candidate

Reuters
·
Feb 23

Top Midday Gainers

MT Newswires Live
·
Feb 06

TransCode Therapeutics Advances Phase 2a Colorectal Cancer Trial

TIPRANKS
·
Feb 05

Transcode Therapeutics, Quantum Leap submit IND for Phase 2a trial of TTX-MC138

TIPRANKS
·
Feb 05

TransCode Therapeutics Submits IND Amendment for Phase 2a Trial of TTX-MC138 in Colorectal Cancer

Reuters
·
Feb 05

Transcode Therapeutics and Quantum Leap Announce Submission of Ind Amendment for Phase 2a Clinical Trial With Ttx-Mc138

THOMSON REUTERS
·
Feb 05

BRIEF-Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026

Reuters
·
Jan 06

Transcode Therapeutics Inc - Ttx-Mc138 Phase 2a Clinical Trial Expected in First Half of 2026 - SEC Filing

THOMSON REUTERS
·
Jan 06

TransCode Therapeutics Reports Preclinical Success of TTX-MC138 in Glioblastoma Models

Reuters
·
Jan 06

TransCode Therapeutics Files Amended 8-K on ABCJ Acquisition

Reuters
·
Dec 24, 2025

Transcode Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Jack E. Stover

Reuters
·
Dec 23, 2025

Transcode Therapeutics Expands Leadership With Appointment of Jack E. Stover to Board of Directors

THOMSON REUTERS
·
Dec 22, 2025

Press Release: TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

Dow Jones
·
Dec 22, 2025

Transcode Therapeutics Inc Files for Mixed Shelf of up to $150 Mln – SEC Filing

THOMSON REUTERS
·
Dec 13, 2025